Comparison of ticagrelor with clopidogrel in Chinse ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention

作者：Jing, Rui; Lin, Wenhua^*

来源：International Journal of Clinical and Experimental Medicine, 2016, 9(12): 23525-23529.

• Acute myocardial infarction
• percutaneous coronary intervention
• ticagrelor
• clopidogrel

Background: Ticagrelor has shown better efficacy and safety in comparison with clopidogrel in acute coronary syndrome patients. However, there is a paucity of evidence supporting the use of ticagrelor in Chinese ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Materials and methods: This is a prospective, randomized, parallel design, investigator initiated, pharmacodynamic study carried out at our hospital from June 2014 to May 2015. Patients were randomized in a 1:1 ratio to receive a loading dose (LD) of clopidogrel 600 mg and aspirin 300 mg (n = 94) or ticagrelor 180 mg and aspirin 300 mg (n = 94). The adenosine diphosphate (ADP) inhibition rate and the maximum amplitude were measured using the thrombelastography at various time points post LD. Results: The ADP inhibition rates at 0.5 h, 1 h, 2 h, and 4 h were significantly higher for ticagrelor in comparison with clopidogrel (P < 0.05). The maximum amplitude at 0.5 h, 1 h, 2 h, and 4 h were significantly lower for ticagrelor in comparison with clopidogrel (P < 0.05). Conclusion: Ticagrelor is more potent with faster onset in comparison with clopidogrel in Chinese STEMI patients treated with primary PCI.

• 出版日期2016
• 单位泰达国际心血管病医院